Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
International Journal of Molecular Sciences|March 28, 2024
State-of-the-Art Differentiation Protocols for Patient-Derived Cardiac Pacemaker CellsEleonora Torre, Matteo E Mangoni, Alain Lacampagne, et al.Basic Research in Cardiology|January 20, 2017
Late sodium current and intracellular ionic homeostasis in acute ischemiaCarlotta Ronchi, Eleonora Torre, Riccardo Rizzetto, et al.The Journal of Physiology|September 13, 2024
Computational modelling of mouse atrio ventricular node action potential and automaticityChiara Bartolucci, Pietro Mesirca, Eugenio Ricci, et al.Cells|April 12, 2022
L-Type Cav1.3 Calcium Channels Are Required for Beta-Adrenergic Triggered Automaticity in Dormant Mouse Sinoatrial Pacemaker CellsJulien Louradour, Olivier Bortolotti, Eleonora Torre, et al.Scientific Reports|November 4, 2020
Concomitant genetic ablation of L-type Cav1.3 (α1D) and T-type Cav3.1 (α1G) Ca2+ channels disrupts heart automaticityMatthias Baudot, Eleonora Torre, Isabelle Bidaud, et al.Frontiers in Physiology|April 26, 2021
Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With TrastuzumabClaudia Altomare, Alessandra Maria Lodrini, Giuseppina Milano, et al.The Journal of Pharmacology and Experimental Therapeutics|September 24, 2022
Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac FunctionMartina Arici, Mara Ferrandi, Paolo Barassi, et al.Journal of Translational Medicine|January 19, 2024
Selective SERCA2a activator as a candidate for chronic heart failure therapyMartina Arici, Shih-Che Hsu, Mara Ferrandi, et al.Nature Communications|January 3, 2024
Selective blockade of Cav1.2 (α1C) versus Cav1.3 (α1D) L-type calcium channels by the black mamba toxin calciseptinePietro Mesirca, Jean Chemin, Christian Barrère, et al.Journal of Medicinal Chemistry|May 17, 2022
Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart FailureAndrea Luraghi, Mara Ferrandi, Paolo Barassi, et al.Pageof 3